𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Tocotrienols have potent antifibrogenic effects in human intestinal fibroblasts

✍ Scribed by Jeroni Luna; Maria Carme Masamunt; Mariana Rickmann; Rut Mora; Carolina España; Salvadora Delgado; Josep Llach; Eva Vaquero; Miquel Sans


Book ID
102861555
Publisher
John Wiley and Sons
Year
2011
Tongue
English
Weight
805 KB
Volume
17
Category
Article
ISSN
1078-0998

No coin nor oath required. For personal study only.

✦ Synopsis


Background: Excessive fibroblast expansion and extracellular matrix (ECM) deposition are key events for the development of bowel stenosis in Crohn's disease (CD) patients. Tocotrienols are vitamin E compounds with proven in vitro antifibrogenic effects on rat pancreatic fibroblasts. We aimed at investigating the effects of tocotrienols on human intestinal fibroblast (HIF) proliferation, apoptosis, autophagy, and synthesis of ECM.

Methods: HIF isolated from CD, ulcerative colitis (UC), and normal intestine were treated with tocotrienol-rich fraction (TRF) from palm oil. HIF proliferation was quantified by 3 H-thymidine incorporation, apoptosis was studied by DNA fragmentation, propidium iodide staining, caspase activation, and poly(ADP-ribose) polymerase cleavage, autophagy was analyzed by quantification of LC3 protein and identification of autophagic vesicles by immunofluorescence and production of ECM components was measured by Western blot.

Results: TRF significantly reduced HIF proliferation and prevented basic fibroblast growth factor-induced proliferation in CD and UC, but not control HIF. TRF enhanced HIF death by promoting apoptosis and autophagy. HIF apoptosis, but not autophagy, was prevented by the pan-caspase inhibitor zVAD-fmk, whereas both types of cell death were prevented when the mitochondrial permeability transition pore was blocked by cyclosporin A, demonstrating a key role of the mitochondria in these processes. TRF diminished procollagen type I and laminin c-1 production by HIF.

Conclusions: Tocotrienols exert multiple effects on HIF, reducing cell proliferation, enhancing programmed cell death through apoptosis and autophagy, and decreasing ECM production. Considering their in vitro antifibrogenic properties, tocotrienols could be useful to treat or prevent bowel fibrosis in CD patients.


📜 SIMILAR VOLUMES


Equally potent inhibitors of cholesterol
✍ L.H. Cohen; R.E.W. van Leeuwen; G.C.F. van Thiel; J.F. van Pelt; S.H. Yap 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 433 KB 👁 1 views

Six 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (the present cholesterol-lowering drugs known as statins), lovastatin (L), simvastatin (S), pravastatin (P), fluvastatin (F), atorvastatin (A) and cerivastatin (C) are shown to be potent inhibitors of cholesterol synthesis in h

Mapping the CRF–urocortins system in hum
✍ Selene Pérez-García; Yasmina Juarranz; Mar Carrión; Irene Gutiérrez-Cañas; Andre 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 679 KB

In addition to the brain and pituitary gland, the corticotrophin-releasing factor (CRF) system is expressed in peripheral tissues. In this study we characterize the expression of CRF, urocortins (UCN1, UCN2, and UCN3), and their receptors (CRFR1 and CRFR2) in osteoarthritis (OA) and rheumatoid arthr

The fragile X mutation does not have any
✍ Ann-Marie Steen; Suzanne Marcus; Sigrid Sahlén; Karen Brøndum Nielsen; Bo Lamber 📂 Article 📅 1991 🏛 Springer 🌐 English ⚖ 280 KB

The possible influence of the fragile X mutation at Xq27 on the expression of the neighbouring gene (at Xq26) for hypoxanthine phosphoribosyl transferase (HPRT) was studied by determination of the levels of HPRT-RNA and HPRT enzyme activity in fibroblast cell cultures from 7 fragile X patients. Thes

Immunotoxins constructed with anti-CD25
✍ Andreas Engert; Gary Martin; Peter Amlot; John Wijdenes; Volker Diehl; Philip Th 📂 Article 📅 1991 🏛 John Wiley and Sons 🌐 French ⚖ 867 KB

## Abstract Twenty‐three monoclonal antibodies (MAbs) against the IL‐2 receptor α‐chain (CD25) were evaluated as ricin A‐chain immunotoxins for the treatment of Hodgkin's disease. Primary screening used an indirect assay in which the cells were treated with the test antibody followed by a Fab immun